Eli Lilly and Company announced results from the long-term extension of the Phase 3 TRAILBLAZER-ALZ 2 study, which evaluates the efficacy and safety of Kisunla (donanemab-azbt) in individuals with early symptomatic Alzheimer's disease. The findings indicate that Kisunla continues to demonstrate a growing benefit over three years, as it slows cognitive decline compared to an untreated external cohort from the Alzheimer's Disease Neuroimaging Initiative. The study highlights the importance of early intervention, showing that earlier initiation of Kisunla significantly reduces the risk of disease progression. These results were presented at the 2025 Alzheimer's Association International Conference in Toronto.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Eli Lilly and Company published the original content used to generate this news brief via PR Newswire (Ref. ID: DE39271) on July 30, 2025, and is solely responsible for the information contained therein.